Related Experiment Videos
Response criteria in research protocols for prostatic cancer
1Department of Urology, Faculty of Medicine, University of Tokyo, Japan.
Progress in Clinical and Biological Research
|January 1, 1990
Summary
The Japanese Response Criteria for Prostatic Cancer (JRCPC) offers a practical approach to evaluating treatment response. Serum PAP levels are the most sensitive indicator for predicting survival in prostate cancer patients.
Area of Science:
- Oncology
- Clinical Research
Background:
- Evaluating treatment efficacy in prostate cancer requires standardized response criteria.
- Existing criteria present challenges in practical application and comparison across studies.
Purpose of the Study:
- To highlight problems with current prostate cancer response criteria.
- To discuss the most practical response criteria for clinical use.
- To present results from a collaborative study using the Japanese Response Criteria for Prostatic Cancer (JRCPC).
Main Methods:
- Utilized the JRCPC, which independently assesses primary prostatic lesions, bone metastases, serum PAP levels, and bidimensionally measurable lesions.
- Evaluated overall response based on individual parameter responses.
- Conducted a multi-institution collaborative clinical study.
Main Results:
- The JRCPC allows for independent assessment of various disease foci.
- Serum PAP levels demonstrated the highest sensitivity in predicting patient survival.
- The parameter-based evaluation facilitates re-evaluation using alternative criteria and cross-study comparisons.
Conclusions:
- The JRCPC provides a flexible framework for evaluating prostate cancer treatment response.
- Serum PAP level is a critical biomarker for predicting survival.
- Further refinement in parameter measurement accuracy is needed to establish definitive response criteria for prostate cancer therapy evaluation.